VERTEX PHARMACEUTICALS INC / MA (VRTX) Company Report

Vertex’s strategy is built on four diversified franchises—cystic fibrosis, heme (Casgevy), pain (suzetrigine) and an emerging renal vertical—supported by a strong and growing balance sheet and ongoing share buybacks.
The renal pipeline’s lead program, povetacicept (POVI), is in the Phase 3 RAINIER trial for IgAN with an interim analysis due H1 2026 under breakthrough and rolling-review designations; its Phase 2 RUBY-3 study showed up to 64% proteinuria reduction at 48 weeks.
Inaxaplin for APOL1-mediated kidney disease (AMKD) is in a seamless Phase 2/3 AMPLITUDE program with an interim readout expected late 2026, following Phase 2 results showing 47.6% proteinuria reduction.
The CF franchise is guided to grow 8–9% in 2026, driven by expansion to younger patients, geographic rollouts of ALYFTREK/Casgevy and label extensions, even as Vertex advances next-gen modulators like VX-828 to outpace competitors.

1 day ago

Transcript

Vertex Pharmaceuticals outlines pipeline and diversification strategy at TD Cowen conference

VRTX

Guidance Update

Share Buyback

CEO Reshma Kewalramani highlighted continued CF leadership, two commercialized verticals (CASGEVY in heme and JOURNAVX in pain), and an emerging fourth franchise in renal with pote in IgAN, supported by a pipeline of five pivotal programs and multiple Phase II assets.
Pove’s Phase III RAINIER trial in IgAN remains on track for an interim analysis in H1 2026, with investors expecting ~47% UPCR reduction; the drug offers once-monthly, low-volume auto-injector dosing and potential across multiple renal indications.
For AMKD (APOL1-mediated kidney disease), Vertex completed enrollment for the Phase III AMPLITUDE interim cohort, with readouts expected late 2026/early 2027; Phase II showed a 47.6% reduction in proteinuria.
CF franchise guidance of 8–9% year-over-year growth is driven by pediatric label expansions, geographic rollout, and ALYFTREK launches (e.g., recent reimbursement in Italy added ~1,500 eligible patients).
Vertex’s strong balance sheet underpins ongoing share buybacks alongside disciplined, disease-first R&D and strategic business development within a “sandbox” of 12–24 target diseases.

1 day ago

Transcript

Vertex outlines pipeline expansion and CF guidance at TD Cowen conference

VRTX

Product Launch

Guidance Update

Share Buyback

Vertex reiterated 8–9% CF franchise growth guidance for 2026, driven by lower-age group approvals and geographic expansions of ALYFTREK (Casgevy), including recent reimbursement in Italy unlocking ~1,500 ultra-rare patients.
The renal franchise advances with povetacicept in IgA nephropathy—Phase 3 interim readout expected H1 2026 targeting up to 47% proteinuria reduction—and inaxaplin in APOL1-mediated kidney disease aiming for 47.6% reduction with interim results due late 2026.
Vertex plans rolling regulatory submissions for povetacicept’s breakthrough-designated accelerated approval in H1 2026 and an accelerated filing for AMKD if Phase 3 readouts are positive.
The R&D pipeline comprises five pivotal programs, multiple Phase 2 assets in heme and pain, and strategic in-licensing (e.g., DM1 from Entrada), backed by a strong balance sheet and expanding share buybacks.

1 day ago

Transcript

Vertex reports Q4 2025 results

VRTX

Earnings

Guidance Update

Share Buyback

Total revenue of $3.2 billion in Q4 (+10% YoY) and $12 billion for FY 2025 (+9%), underpinned by the CF franchise.
CF revenue grew 7% globally; CASGEVY delivered $54 million in Q4 ( $116 million FY 2025) and JOURNAVX contributed $27 million in Q4 ( $60 million FY 2025).
2026 guidance: revenue of $12.95 billion–$13.1 billion (+8%–9%), including > $500 million from non-CF products; non-GAAP operating expenses of $5.65 billion–$5.75 billion; tax rate 19.5%–20.5%.
Pipeline highlights: ALYFTREK Phase III in 2–5 year-olds showed a 9.6 mmol reduction in sweat chloride, with global regulatory submissions on track for H1 2026 ; povetacicept BLA submission rolling with Breakthrough Therapy designation and membranous nephropathy study (OLYMPUS) advancing as planned.
Strong balance sheet with $12.3 billion cash, equivalents and marketable securities; repurchased ~ 4.8 million shares for $2 billion in 2025; Q4 gross margin of 85.7%.

Feb 12, 2026, 9:30 PM

Transcript

Vertex Pharmaceuticals reports Q4 2025 results

VRTX

Earnings

Guidance Update

Total revenue of $3.2 billion in Q4 (+10% YoY) and $12 billion for FY 2025 (+9%).
CF therapies drove FY growth with global CF revenue up 7% (US +11%, ex-US +2%).
Non-CF products: CASGEVY delivered $54 million in Q4 ( $116 million FY) and Dravenax $27 million in Q4 ( $60 million FY).
2026 guidance: revenue of $12.95–13.10 billion (+8–9%), >$500 million from non-CF, operating expenses of $5.65–5.75 billion, and a tax rate of 19.5–20.5%.

Feb 12, 2026, 9:30 PM

Transcript

Vertex Pharmaceuticals reports Q4 2025 results

VRTX

Earnings

Guidance Update

Product Launch

FY 2025 revenue grew 9% Y/Y to $12.00 B, driven by the cystic fibrosis portfolio; Q4 product revenues were $3.19 B (TRIKAFTA/KAFTRIO $2.57 B; ALYFTREK $380 M).
Q4 non-GAAP operating income was $1.37 B with a 43% non-GAAP operating margin and non-GAAP diluted EPS of $5.03.
FY 2026 guidance calls for total revenues of $12.95 – 13.1 B, combined non-GAAP R&D, acquired IPR&D & SG&A expenses of $5.65 – 5.75 B, and an effective tax rate of 19.5 – 20.5%.
Pediatric regulatory submissions are planned in H1 2026 for TRIKAFTA (ages 1-2) and ALYFTREK (ages 2-5), and CASGEVY delivered $116 M in FY 2025 revenue with ongoing infusion acceleration.

Feb 12, 2026, 9:30 PM

Presentation

Vertex Pharmaceuticals reports Q4 2025 results

VRTX

Earnings

Guidance Update

Product Launch

Total Q4 revenue reached $3.2 billion (+10% YoY) and FY 2025 revenue was $12 billion (+9%)
Cystic fibrosis (CF) franchise grew 7% globally, with U.S. CF revenue +11% and international +2%
Diversified portfolio: CASGEVY generated $54 million in Q4 ( $116 million FY), and JOURNAVX delivered $27 million in Q4 ( $60 million FY)
2026 guidance: total revenue of $12.95–13.10 billion (8–9% growth), non-GAAP operating expenses of $5.65–5.75 billion, and ≥ $500 million from non-CF products
Pipeline highlights: positive ALYFTREK Phase III results in 2–5 year-olds with a global submission planned in H1 2026 ; povetacicept BLA rolling review with Breakthrough Therapy designation

Feb 12, 2026, 9:30 PM

Transcript

Vertex reports Q4 and FY 2025 results

VRTX

Earnings

Guidance Update

Vertex delivered Q4 2025 total revenue of $3.19 billion, up 10 % year-over-year.
Full year 2025 revenue reached $12.0 billion, a 9 % increase vs 2024.
Q4 GAAP net income was $1.2 billion (non-GAAP $1.3 billion), and full year GAAP net income was $4.0 billion (non-GAAP $4.7 billion).
Vertex issued 2026 guidance for $12.95–13.1 billion in total revenue, including ≥$0.5 billion from non-CF products.
The mid-/late-stage pipeline accelerated, with plans to complete the BLA filing for povetacicept in IgAN in H1 2026.

Feb 12, 2026, 9:04 PM

8-K

Vertex reports Q4 and full year 2025 financial results

VRTX

Earnings

Guidance Update

Q4 total revenue of $3.19 B, up 10% YOY; full year total revenue of $12.0 B, up 9% YOY.
Q4 GAAP net income of $1.2 B and non-GAAP net income of $1.3 B; FY 2025 GAAP net income of $4.0 B and non-GAAP net income of $4.7 B.
Q4 combined GAAP R&D, AIPR&D and SG&A expenses of $1.52 B and non-GAAP of $1.36 B; FY 2025 combined GAAP expenses of $5.8 B and non-GAAP of $5.1 B.
Cash, cash equivalents and marketable securities stood at $12.3 B as of December 31, 2025, up from $11.2 B a year earlier.
FY 2026 guidance: total revenue of $12.95–13.10 B; non-CF product revenue ≥ $0.5 B; combined non-GAAP R&D, AIPR&D and SG&A expenses of $5.65–5.75 B.

Feb 12, 2026, 9:01 PM

Press Release

Vertex outlines 2026 commercial and pipeline priorities at JPM Healthcare Conference

VRTX

Product Launch

Guidance Update

New Projects/Investments

Vertex plans to sustain CF leadership into 2037 and beyond, driven by the global roll-out of Vanzacaftor and continued Trikafta/Kaftrio launches, leveraging 95% patient eligibility and modelled survival into the 80s with early treatment.
Casgevy reached over $100 million in 2025 revenues, with filings for 5–11-year-olds planned in 2026 under the priority review voucher, as Vertex targets multi-billion-dollar potential across the U.S., Europe and Middle East.
Jurnavix, launched in January 2025 for moderate-to-severe acute pain, amassed 500,000 prescriptions by year-end, saw Q4 scripts grow 50% sequentially, and aims to triple prescriptions in 2026 by doubling its field force and expanding payer coverage to two-thirds of Americans.
The Povy (povetacicept) IgAN submission is underway under Breakthrough designation, targeting accelerated U.S. approval in H1 2026; the monthly, 0.46 mL auto-injector is positioned for best-in-class efficacy, safety and patient adherence.
Vertex’s emerging renal franchise now encompasses four mid-/late-stage programs (IgAN, AMKD, ADPKD, APOL1), with APOL1 interim data expected late 2026 and potential accelerated filing thereafter.

Jan 12, 2026, 10:15 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for VERTEX PHARMACEUTICALS INC / MA.

Q4 2025

Feb 12, 2026

→

Q3 2025

Nov 3, 2025

→

Q2 2025

Aug 4, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Reshma Kewalramani say about margins?What are VERTEX PHARMACEUTICALS INC / MA's strategic priorities?How is VERTEX PHARMACEUTICALS INC / MA positioned vs competitors?How did VERTEX PHARMACEUTICALS INC / MA do last quarter?

VERTEX PHARMACEUTICALS INC / MA (VRTX)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Reshma Kewalramani

Jeffrey Leiden

Charles Wagner

David Altshuler

Duncan McKechnie

Jonathan Biller

Board Members

Alan Garber

Bruce Sachs

Diana McKenzie

Jennifer Schneider

Lloyd Carney

Michel Lagarde

Nancy Thornberry

Sangeeta Bhatia

Suketu Upadhyay

Analyst Coverage

Evan Seigerman

Salveen Richter

Tazeen Ahmad

Michael Yee

Jessica Fye

Philip Nadeau

William Pickering

David Risinger

Ellie Merle

Geoff Meacham

Liisa Bayko

Terence Flynn

Brian Abrahams

Cory Kasimov

Eliana Merle

Geoffrey Meacham

Justin Morrison

Mohit Bansal

Olivia Brayer

Chris

Debjit Chattopadhyay

Divya Rao

Huidong Wang

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent